Core Insights - Fortinet, Inc. is under investigation for potential violations of federal securities laws following its second quarter 2025 financial results [1][2] - The company reported that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" and provided weaker-than-expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [2] - Following this announcement, Fortinet's stock price dropped by $21.28, or 22%, closing at $75.30 per share on August 7, 2025, resulting in losses for investors [3] Investigation Details - The Law Offices of Frank R. Cruz are investigating Fortinet on behalf of investors who may have lost money due to the company's recent disclosures [1][2] - Investors are encouraged to inquire about potentially pursuing claims to recover their losses [2][4]

Core Viewpoint - Barnes & Noble Education, Inc. is under investigation for potential violations of federal securities laws following disclosures of financial misstatements and overstatements in accounts receivable [1][2][3] Financial Disclosures - On July 18, 2025, Barnes & Noble revealed a potential overstatement of up to $23.0 million in accounts receivable as of May 3, 2025, leading to a 21% drop in stock price [2] - On August 29, 2025, the company announced that its financial statements for the fiscal year ended April 27, 2024, through the quarter ended January 25, 2025, should no longer be relied upon due to issues related to revenue recognition and actions of a payment processing employee [3] Legal and Investor Actions - Glancy Prongay & Murray LLP is representing investors who may have lost money on Barnes & Noble's stock and is encouraging them to inquire about potential claims [2] - The law firm is also seeking whistleblowers with non-public information to aid in the investigation, offering rewards under the SEC Whistleblower Program [5]

Core Points - Glancy Prongay & Murray LLP is investigating AVITA Medical, Inc. for potential violations of federal securities laws [1] - AVITA Medical reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of 2025 [2] - The company's stock price dropped by 21%, closing at $4.25 per share following the announcement of the backlog [2] Company Summary - AVITA Medical, Inc. (NASDAQ: RCEL) is facing scrutiny due to a backlog of unpaid claims related to its wound care product, Recell, which has created uncertainty among providers [2] - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims [2] Legal Context - Investors who lost money on AVITA Medical are encouraged to inquire about potential claims to recover losses [2] - The investigation by Glancy Prongay & Murray LLP may lead to legal actions if violations are confirmed [1][2]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

In the wake of FTX cryptocurrency fraud, investors claim Silvergate Bank misled the public about its customer vetting and anti-money laundering programs. Subsequent run on the bank led to Silvergate Bank’s demise and Silvergate Capital’s bankruptcy. SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Today, a federal judge in California granted final approval of a $37.5 million cash settlement between investors and Silvergate Capital Corporation, the holding company for Silvergate Bank, resolving a securities fr ...

Core Viewpoint - Fortinet, Inc. is under investigation for potential violations of federal securities laws following the release of its second quarter 2025 financial results, which included weaker-than-expected revenue guidance and updates on its firewall upgrade cycle [1][2]. Financial Performance - On August 6, 2025, Fortinet reported that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" at the end of the second quarter [2]. - The company projected third quarter revenue between $1.67 billion and $1.73 billion, which was below market expectations [2]. Stock Market Reaction - Following the announcement of the financial results and guidance, Fortinet's stock price dropped by $21.28, or 22%, closing at $75.30 per share on August 7, 2025 [3].

Core Viewpoint - Barnes & Noble Education, Inc. is under investigation for potential violations of federal securities laws following disclosures of financial misstatements and overstatements in accounts receivable [1][3][4] Group 1: Financial Disclosures - On July 18, 2025, Barnes & Noble revealed a potential overstatement of up to $23.0 million in accounts receivable as of May 3, 2025, due to issues related to the recording of digital sales [3] - Following this announcement, the company's stock price dropped by $2.36, or 21%, closing at $8.87 per share on July 21, 2025 [3] - On August 29, 2025, the company disclosed that its previously issued financial statements for the fiscal year ended April 27, 2024, through the quarter ended January 25, 2025, should no longer be relied upon due to internal investigation findings [4] Group 2: Causes of Financial Misstatements - The company identified two main causes for the financial misstatements: actions of a payment processing employee and certain sales that did not meet the criteria for revenue recognition [4]

Core Viewpoint - AVITA Medical, Inc. is under investigation for potential violations of federal securities laws following a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted the company's financial performance and stock price [1][2]. Financial Performance - On August 7, 2025, AVITA reported its second quarter 2025 financial results, indicating a six-month backlog in unpaid provider claims for Recell procedures, which affected first-half demand [2]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers and reduced utilization of Recell [2]. - Following the announcement, AVITA's stock price dropped by $1.13, or 21%, closing at $4.25 per share on August 8, 2025, resulting in financial harm to investors [2].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its revenue projections and the impact of its CEO's health on operations [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased C3's securities between February 26, 2025, and August 8, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against C3.ai - The complaint alleges that C3.ai made false and misleading statements that led investors to believe the company could reliably project its revenues and growth [4]. - The company downplayed the risks associated with the health concerns of CEO Thomas M. Siebel, which ultimately affected its optimistic projections for growth, earnings, and margins [4]. - When the truth about C3's operations and the impact of the CEO's health became known, investors suffered damages [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its competitive position and financial guidance [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD misled investors about its competitive position and raised its fiscal year 2025 performance guidance without proper justification [4]. - The company reportedly ignored critical factors such as customer acquisition costs for weight loss drugs, leading to materially misleading public statements throughout the class period [4]. - As a result of the misleading information, investors suffered damages when the truth about LifeMD was revealed [4].